CASC3 and non-small cell lung carcinoma: Phase 3 clinical trials are currently underway using BTZ as a therapy to treat NSCLC (i.e., NCT01833143), and second-generation proteasome inhibitors are being applied in phase 4 trials (e.g., NCT03416374).